Lavrov V N
Probl Tuberk. 1994(5):32-4.
The author summarized the data on experimental application of biocompatible implants IIIIIM-1 covered with benemycin as a treatment modality in spondylitis. The polymer implanted into the disease focus is able to maintain high concentration of the drug for 60 days. The implants were inserted in 120 tuberculous and 27 nonspecific spondylitis patients. Surgical intervention performed in 147 patients comprising radical resection of the destruction focus and vertebral defect replacement with biocompatible implant in combination with extrafocal apparatus fixation decreased the operation trauma++, secured stability of the anterior and posterior parts of the operated spine and allowed early active rehabilitation of postoperative patients, 2-3 months after the surgery the author observed good spinal stabilization and definite signs of clavus formation in the resection zone.
作者总结了关于覆盖有苯霉素的生物相容性植入物IIIIIM-1在脊柱炎实验应用中的数据，作为一种治疗方式。植入病灶的聚合物能够在60天内保持药物的高浓度。这些植入物被插入120例结核性和27例非特异性脊柱炎患者体内。对147例患者进行了手术干预，包括对破坏病灶进行根治性切除，并用生物相容性植入物替代椎体缺损，并结合病灶外器械固定，减少了手术创伤++，确保了手术脊柱前后部的稳定性，并使术后患者能够早期积极康复。术后2至3个月，作者观察到脊柱稳定良好，切除区域有明显的瘢痕形成迹象。
